Advanced searches left 3/3

Gonorrhea - Europe PMC

Summarized by Plex Scholar
Last Updated: 11 June 2022

* If you want to update the article please login/register

Systematic Review and Meta-Analysis to Estimate the Treatment Effect and Inform a Non-Inferiority Margin for a Phase 3 Non-Inferiority Trial in Uncomplicated Urogenital Gonorrhea.

"Background As placebo-controlled studies are unethical, active-controlled non-inferiority experiments are used to identify novel agents for uncomplicated urogenital gonorrhea. The ceftriaxone and proxy-for-placebo microbiological therapy effects were estimated by a systematic literature review and meta-analysis to determine the ceftriaxone and proxy-for-placebo microbiological treatment effect and determine a proper non-inferiority margin for phase 3 trials. Results Seventeen studies were included in the meta-analysis; 14 reported ceftriaxone response in micro-intent-to-treat and microbiologically evaluable populations, three described proxy-for-placebo treatment reactions in uUGC; three others did not; three others did not; four evaluable populations were included; four researchers reported ceftriaxone response in micro-intent-to-treat and microbiologically evaluable The effect of microbiological therapy was estimated by subtracting the placebo portion of the CI for ceftriaxone from the lower end of the CI for ceftriaxone. Overall microbiological response was 98% for ceftriaxone and 44% for proxy-for-placebo, resulting in a microbiological treatment effect of 43 percent. A non-inferiority margin of 15% retained 65% of the ceftriaxone treatment results, far above the 50% recommended by the U. S. Food and Drug Administration for non-inferiority studies. ".

Source link: https://europepmc.org/article/MED/35675712


Rapid Uptake of Testing for Chlamydia, Gonorrhea, and HIV From an Online Platform, April-October 2020.

"When COVID-19 restricted in-person clinic services, the Baltimore City Health Department sold IWantTheKit for chlamydia, gonorrhea, and HIV testing to city residents and clinic patients. A high prevalence of chlamydia and gonorrhea was found, and 96% of patients who tested positive for chlamydia and gonorrhea were successfully contacted for medical attention.

Source link: https://europepmc.org/article/MED/35617664


Assessing the impact of HIV pre-exposure prophylaxis scale-up on gonorrhea incidence among gay and bisexual men in Sydney: a mathematical modelling study.

"Background The rollout of pre-exposure prophylaxis for HIV prevention among gay and bisexual men has been correlated with an increase in condomless anal intercourse, presumably raising the risk of other sexually transmissible infections. " During 2010 to 2019, We calibrated and validated the model using estimated incidence rates for HIV-positive and HIV-negative GBM. Scenarios were conducted with varying PrEP uptake, PrEP-related STI testing, and PrEP-related sexual use, with reporting intervals up to 2030 to determine the effect of PrEP use on gonorrhea use. Since 2018's figures regarding HIV-negative GBM, the incidence rate of HIV-positive GBM rises by 8% by 2030, increasing the time between STI tests for PrEP users by one month from 2018. Conclusions Behavior change in conjunction with widespread PrEP use can lead to significant rises in gonorrhea infections in GBM, but the recommended quarterly STI testing for PrEP users should reduce incidence by 18% by 2030. ".

Source link: https://europepmc.org/article/MED/35608079


Community engagement on-site rapid test for chlamydia and gonorrhea among men who have sex with men: a pioneering study in Guangzhou, China.

"Background Chlamydia trachomatis and Neisseria gonorrhoeae infections are common among males in China's sex with men. " The aim of this pilot study was to determine the possibility of running a rapid nucleic acid test for chlamydia and gonorrhea in MSM community-based organizations. Positive cases were sent on-site and tested for chlamydia and gonorrhea on-site, and the test findings were published in about 1. 5 hrs. The gonorrhea's positive rate was 16. 3% and 3. 8 percent, respectively. Only 19. 3% of participants had undergone chlamydia and gonorrhea testing, and 68. 9% said they had never heard of gonorrhea, although 47. 4% had never heard of chlamydia. Conclusions This pilot study found that the chlamydia and gonorrhea infection rate among MSM is still high, despite the fact that the testing rate was low. ".

Source link: https://europepmc.org/article/MED/35606713

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions